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Antifibrinolytic Therapy and Perioperative Blood Loss in
Cancer Patients Undergoing Major Orthopedic Surgery
David Amar, M.D.,* Florence M. Grant, M.D.,† Hao Zhang, M.D.,‡ Patrick J. Boland, M.D.,§ Denis H. Leung, Ph.D.,
John A. Healey, M.D.#
Background: Aprotinin has been reported to reduce blood
loss and transfusion requirements in patients having major
orthopedic operations. Data on whether  amino–caproic acid
(EACA) is effective in this population are sparse.
Methods: Sixty-nine adults with malignancy scheduled for
either pelvic, extremity or spine surgery during general anes-
thesia entered this randomized, double-blind, placebo-con-
trolled trial, and received either intravenous aprotinin (n  23),
bolus of 2  106 kallikrein inactivator units (KIU), followed by
an infusion of 5  105 KIU/h, or EACA (n  22), bolus of
150 mg/kg, followed by a 15 mg/kg/h infusion or saline placebo
(n  24) during surgery. Our goal was to determine whether
prophylactic EACA or aprotinin therapy would reduce periop-
erative blood loss (intraoperative  first 48h) >30% when com-
pared to placebo.
Results: The mean age of the study population was 52  17 yr.
The groups did not differ in age, duration of surgery, perioper-
ative blood loss or number of packed erythrocyte units trans-
fused. When compared to the placebo group, the two treated
groups had a significantly lower D-Dimer level immediately
after surgery, P < 0.01.
Conclusions: Under the conditions of this study, we were
unable to find a clinical benefit to using aprotinin or EACA to
reduce perioperative blood loss or transfusion requirements
during major orthopedic surgery in cancer patients.
MAJOR orthopedic surgery can be associated with sub-
stantial perioperative blood loss requiring transfusion of
multiple units of blood. One of the contributing mech-
anisms to increased blood loss during orthopedic oper-
ations involves an imbalance of the coagulation and
fibrinolytic systems in response to major bleeding, endo-
thelial and bone trauma, and absorption of bone ce-
ment.1 Transfused blood has been associated with im-
munomodulation and increased postoperative infection,
transmission of infectious diseases, acute lung injury and
increased costs.2 Patients with cancer frequently present
with various degrees of anemia secondary to chemother-
apy, bleeding, or the malignancy itself, and are therefore
more likely to require transfusion during surgery. As a
group, they represent an immunocompromised popula-
tion who suffer greater morbidity from postoperative
infection. Several of the blood salvage techniques avail-
able to other surgical populations such as preoperative
autologous blood donation or intraoperative cell salvage
and retransfusion are controversial and often contraindi-
cated in patients with malignancy or certain systemic
diseases.3
The prophylactic administration of the antifibrinolytic
agent aprotinin was shown to reduce perioperative
blood loss in patients undergoing cardiac or major or-
thopedic surgery including that for tumor resection.4–10
The -aminocaproic acid (EACA), an antifibrinolytic
agent with potential advantages over aprotinin including
substantially lower cost and no risk of anaphylaxis, has
been shown to be as cost-effective as aprotinin in cardiac
surgery but has not been studied in well-controlled trials
of patients undergoing orthopedic surgery.11 Thus, the
primary objectives of the study were to compare the
efficacy of EACA versus aprotinin or placebo to reduce
perioperative blood loss and the number of units of
packed red blood cells (PRBC) transfused during major
orthopedic or spine surgery. We also examined whether
the incidence of postoperative wound infection or deep




This study was approved by the Institutional Review
Board of Memorial Sloan-Kettering Cancer Center and
written informed consent was obtained from each pa-
tient before operation. Included were adult patients
scheduled for any of the following operations to treat
primary or metastatic musculoskeletal neoplasms: total
hip replacement, long bone rodding, total knee replace-
ment, sacrectomy, resection of tumor in bone, spinal
fusion or posterior spinal fixation and stabilization. Ex-
cluded were patients who were 18 yr of age, and had
a known or suspected allergy to either drug, previous
exposure to aprotinin, preoperative renal insufficiency
(creatinine level 1.3 mg/dl), preoperative hepatic in-
sufficiency defined as an elevation 1.5 times normal of
lactic acid dehydrogenase, or serum glutamic oxaloace-
tic transaminase, or serum glutamic pyruvate transami-
nase, history of thromboembolic disease, preoperative
coagulopathy, coronary artery disease, cerebrovascular
disease, congestive heart failure, or current pregnancy.
Five patients were excluded from the study after ran-
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domization but before the study medication was given.
These patients were not included in the intention-to-
treat analysis since the exclusion criteria were identified
before initiating the study.
Anesthesia, Operation, and Perioperative Care
Preoperative medications were continued until the
time of surgery. During and after surgery all patients
received DVT prophylaxis with compression/decom-
pression boots. All patients received standard anesthetic
management that consisted of isoflurane and nitrous
oxide in oxygen supplemented by intravenous fentanyl
and morphine as needed. During surgery, an attempt
was made to maintain a mean arterial pressure between
60 and 70 mmHg using isoflurane and small (5 mg)
incremental doses of intravenous boluses of labetalol if
needed. Fluid warmers and heated body blankets were
used to maintain the patient’s temperature above
35.4°C. Patients were randomized to one of three exper-
imental treatment arms: aprotinin, EACA, or placebo.
Randomization of patients in blocks of 20 were done by
the Biostatistics Department and the hospital pharmacy
using sealed, opaque treatment-code envelopes. All pa-
tients and clinical and study personnel were blinded to
the study group assignments throughout the trial. Intra-
venous preparations of the active drugs and placebo
were prepared by the hospital pharmacy according to a
computer-generated list that was kept confidential until
formal unbinding by the biostatistician at the preselected
analysis.
After anesthetic induction, patients randomized to
aprotinin received a bolus of 2  106 kallikrein inactiva-
tor units (KIU) given over 30 min followed by an infu-
sion of 5  105 KIU/h until the end of surgery. Patients
randomized to EACA received 150 mg/kg EACA bolus in
an equal volume given over 30 min, followed by an
infusion of 15 mg · kg1 · h1 until the end of surgery.
Patients randomized to the placebo arm received an
equal volume of normal saline bolus and infusion. Peri-
operative blood loss was estimated by suction losses and
weighed sponges during surgery and by the volume of
wound drainage for the next 48 h postoperatively. Serial
hemoglobin and hematocrits were measured intraoper-
atively based on the extent of surgical bleeding and daily
after surgery. The PRBC were administered if the hemo-
globin was less than 8.0 g/dl or hematocrit was less than
24% with a goal to maintain the hematocrit at approxi-
mately 28%. Platelet concentrates were administered
only when clinically significant bleeding was observed
and platelet count was 100,000 per microliter. We
used these trigger points based on our transfusion prac-
tice considering our patients often present for surgery
after extensive antineoplastic and radiation therapy
which may cause residual bone marrow suppression and
platelet dysfunction. The number of PRBC units trans-
fused was totaled through postoperative day 2. Determi-
nation of complete blood count, prothrombin time (PT),
and activated partial thromboplastin time (aPTT) was
done during surgery if bleeding was extensive or there
was evidence of a clinical coagulopathy, upon arrival of
the patient to the postanesthesia care unit and on post-
operative day 2. Postoperative pain relief was provided
to all patients by continuous administration of intrave-
nous opioid (usually morphine) patient-controlled anal-
gesia. The patients were evaluated for the presence of
wound infection and for proximal DVT by daily clinical
exam and Doppler ultrasonography performed once be-
tween postoperative days 4 and 6. Major postoperative
cardiac complications recorded were: unstable angina
defined as recurrent or persistent ischemic cardiac pain
at rest with electrocardiogram changes, myocardial in-
farction documented by new Q waves of at least 0.04 s
duration and a minimum of 1 mm depth on 12-lead
electrocardiograph or elevation of creatine kinase–myo-
cardial band (CK-MB) or troponin I levels, and conges-
tive heart failure defined as a clinical diagnosis based on
the presence of rales, increased pulmonary capillary
wedge pressure, or classic chest radiographic findings.
Major postoperative pulmonary complications recorded
were: pulmonary embolism diagnosed by spiral com-
puted tomography and/or ventilation/perfusion lung
scans when clinical parameters (pleuritic chest pain,
hypoxemia, pulmonary rub) were present, pneumonia
requiring antibiotic therapy or respiratory failure requir-
ing mechanical ventilation. Other clinical end points
recorded throughout the hospital stay were renal failure
or insufficiency and death. Patients were monitored for
similar complications as outpatients for 30 days.
Statistical Analysis
The calculation of sample size for this trial was based
on retrospective data from our institution showing that
similar consecutive patients (n  50) had an average of
1.2  0.9 l intraoperative blood loss. In order to detect
at least a 30% difference (considered clinically impor-
tant) in total (48 h) blood loss between the three arms
with a power of 80% and a type 1 error of 5% and using
a group sequential design with one interim analysis at
mid-study, we estimated that a sample size of 105 pa-
tients per arm would be needed. However, due to a
much slower accrual rate (25%) than anticipated and the
inherent risk of administering these drugs to cancer
patients at a greater risk for postoperative thromboem-
bolic events, it was decided to perform an early interim
analysis. Four different stochastic curtailment methods
(three conditional power approaches12–14 and one of
predictive power15) were used with calculations using a
FORTRAN program written by one of the authors
(D.H.L.). In the method of stochastic curtailment current
data are used to project the power for finding a signifi-
cant difference between two treatment arms if the trial
were to continue to completion. These methods showed
338 AMAR ET AL.
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that even if we had accrued the planned 315 patients,
the power to detect a significant treatment effect of
aprotinin or EACA over placebo was extremely low.16
Upon consultation with members of the Institutional
Review Board it was decided to stop the trial. Other
statistical analyses were performed with the software
SPSS version 10.1 (SPSS, Chicago, IL). All analyses were
performed on an intention-to-treat basis and all P values
are two-tailed. A P value less than 0.05 was considered
significant. Data that were not normally distributed (es-
timated blood loss, number of PRBC units transfused,
D-Dimer levels) were log transformed before analysis.
Univariate analysis consisted of Student t test, chi-square
test or Fisher exact test. Repeated measures analysis of
variance was done for testing differences in laboratory
values among the study groups. Data are presented as
mean value  SD unless otherwise indicated.
Results
Patient characteristics and type of operation are shown
in table 1. The groups did not differ in age, duration of
surgery, percent of patients in whom controlled hypo-
tension was achieved throughout the operation or in
duration of hospital stay. Estimated blood loss measured
during surgery and in the first postoperative 48 h did not
differ among the groups (table 2). Similarly, the number
of PRBC units transfused during surgery or in the first
48 h after surgery did not differ among the groups (table
2). To evaluate the effect of controlled hypotension on
bleeding, we compared total blood loss measurements
between patients who did and did not achieve hypoten-
sion throughout the study infusion and found that none
of the comparisons were significantly different within
the three groups: placebo 1.6  0.8 versus 1.6  1.7 l,
P  0.99; aprotinin 1.6  1.2 versus 1.8  1.0 l, P 
0.56; EACA 1.7  1.1 versus 1.5  1.2 l, P  0.75,
respectively. The use of fresh frozen plasma or platelets
was low and did not differ among the groups: two
patients required both fresh frozen plasma (3–4 units)
and platelets (6 units) and were assigned to placebo or
EACA and two patients required only fresh frozen
plasma (2–4 units) and were treated with aprotinin or
EACA. The aPTT levels in the postanesthesia care unit








Age, yr 48  17 53  18 55  16
Gender (M/F), n 13/10 11/11 13/11
Weight, kg 80  24 76  17 83  20
Operation type, n
Spine 7 7 3
Hip 5 8 11
Other 11 7 10
Operative time, min 291  160 368  203 284  148
Intraoperative fluids
Crystalloid, l 4.8  2.7 5.0  3.1 4.3  2.1
Colloid, l 0.4  0.6 0.3  0.5 0.4  0.6
Controlled hypotension, n (%) 10 (43) 7 (32) 9 (38)
Hospital stay, days 9.8  5.3 11.9  7.3 9.0  5.9
There were no significant differences among the groups.
EACA  -aminocaproic acid.








Intraoperative 1.0 (0.3, 2.0) 0.9 (0.5, 1.6) 0.9 (0.4, 1.4)
1.2  1.0 1.3  1.1 1.0  0.9
Total 1.4 (0.9, 2.6) 1.2 (0.6, 2.3) 1.3 (0.6, 1.9)
1.7  1.0 1.6  1.1 1.6  1.4
Packed erythrocytes, number of units
Intraoperative 0 (0, 3) 0 (0, 2) 0.5 (0, 2)
1.1  1.4 1.4  2.2 1.3  1.8
Total 0 (0, 3) 1 (0, 2) 1 (0, 2)
1.8  1.5 1.7  2.5 1.8  2.5
Data are shown as median (25%, 75% quartiles) followed by mean  SD. Total includes intraoperative and first 48 h after surgery. There were no significant
differences among the groups.
EACA  -aminocaproic acid; EBL  estimated blood loss.
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were modestly greater for aprotinin versus EACA (P 
0.01) or placebo (P  0.01) groups (table 3). Hemoglo-
bin, hematocrit, platelet count, and PT measurements
did not differ perioperatively among the groups (table
3). When compared to the placebo group, the two
treated groups had a significantly lower D-Dimer level
immediately after surgery, P  0.01, respectively (table
3). A subgroup analysis for estimated blood loss and
transfusion requirements omitting patients who had
spine surgery showed no significant differences among
the groups (table 4).
Compliance with Treatment and Adverse Effects
One patient developed acute intraoperative broncho-
spasm after receiving aprotinin for 30 min, which was
possibly related to aprotinin administration and there-
fore discontinued. All other patients completed the
study infusion protocol. DVT occurred in three patients
who received EACA and three in the placebo group.
Pulmonary embolism occurred in two patients random-
ized to aprotinin and in one patient in the placebo
group. The overall incidence of postoperative DVT (9%)
or pulmonary embolism (4%) did not differ among the
groups, P  0.72. Other postoperative complications
included: one case of thrombocytopenia (placebo
group), one case of respiratory failure in a patient who
received 9 units of PRBC following a thoracic laminec-
tomy for metastatic renal cell carcinoma (EACA group)
and two cases of wound infection (EACA and placebo
groups).








Preoperative 13.2  2.1 12.7  2.2 12.6  1.6
PACU 11.2  1.3 10.4  1.4 10.5  1.3
POD2 10.2  1.4 10.5  1.3 9.9  1.3
Hematocrit, %
Preoperative 37.9  8.5 38.3  5.6 37.8  4.7
PACU 33.2  3.7 31.4  4.4 31.0  3.7
POD2 30.5  4.3 31.8  3.4 29.7  4.0
Platelet count,  103/dl
Preoperative 261  75 279  108 306  134
PACU 220  85 213  86 262  137
POD2 201  86 194  85 244  121
Prothrombin time, s
Preoperative 11.9  1.0 11.7  0.9 12.1  0.8
PACU 13.0  1.5 13.2  1.8 13.0  1.0
POD2 14.2  5.1 12.4  1.4 13.2  1.1
aPTT, s
Preoperative 29.1  2.9 27.3  3.2 29.1  2.7
PACU 34.5  8.2* 26.5  4.3 26.4  2.2
POD2 29.7  7.6 26.6  2.6 26.7  2.1
D-Dimer, ng/ml
PACU 1.0  1.1 0.6  0.5 2.6  2.5†
*P  0.01, aprotinin versus -aminocaproic acid (EACA) or placebo groups. †P  0.01, placebo versus EACA or aprotinin groups.
aPTT  activated partial thromboplastin time; POD2  postoperative day 2.








Intraoperative 1.0 (0.3, 2.0) 0.9 (0.6, 1.2) 0.7 (0.3, 1.1)
1.2  1.0 1.1  0.8 0.9  0.9
Total 1.7 (0.7, 2.3) 1.1 (0.6, 2.2) 1.1 (0.6, 1.8)
1.7  1.0 1.5  1.0 1.5  1.4
Packed erythrocytes, number of units
Intraoperative 0 (0, 2) 0 (0, 2) 0 (0, 2)
0.8  1.2 1.0  1.6 1.1  1.7
Total 1 (0, 2) 1 (0, 2)
1.1  1.6 1.2  1.8 1.6  2.4
Data are shown as median (25%, 75% quartiles) followed by mean  SD. Total includes intraoperative and first 48 h after surgery. There were no significant
differences among the groups.
EACA  -aminocaproic acid; EBL  estimated blood loss.
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Discussion
Under the conditions of this study, neither aprotinin
nor EACA reduced perioperative blood loss or red blood
cell transfusion requirements when compared to pla-
cebo treated controls. Our study was terminated before
full accrual of the projected sample size based on the
results of an early interim analysis showing that intraop-
erative blood loss was nearly identical across all three
arms and similar to that of a historical cohort on which
the study sample-size power calculation was based. For
the treatment to be clinically meaningful we hypothe-
sized that there would need to be a reduction in esti-
mated blood loss of at least 30% with either treatment in
comparison to placebo. Our futility analysis indicated
that unless the remaining patients to be enrolled into the
treatment arms of this study had at least a 50% reduction
in blood loss in comparison to the placebo group, we
would not be able to show a benefit to using either drug
in this patient population.16 As this was very unlikely we
decided to end the trial. Although not accruing the full
sample size is a limitation of the study, we had a com-
parable or greater number of patients in each of the
treatment arms as in other studies examining the use of
antifibrinolytic agents in orthopedic surgery.6–10 We ac-
knowledge that there is some anatomic heterogeneity in
our population but our patients were a physiologically
homogenous group selected based on our historical re-
view of similar cases at risk for major blood loss during
resection. These patients had similar exposure to anti-
neoplastic therapy and were treated by a focused group
of surgeons. The results showing no differences in blood
loss among the groups with all the patients included or
with the spine patients removed further validate our
decision to include these patients in the study.
Our study used general anesthesia, and moderate hy-
potensive technique throughout the operation was
achieved in an average of 38% of our patients. A separate
analysis of blood loss with or without controlled hypo-
tension showed no differences among the groups. The
antifibrinolytic effect of aprotinin or EACA was con-
firmed by significantly lower immediate postoperative
D-Dimer levels when compared to placebo. Aprotinin
treated patients had a statistically but not clinically sig-
nificant increase in aPTT immediately after surgery. This
rise in aPTT but not in PT is likely associated with
aprotinin’s known inhibition of kallikrein and the intrin-
sic coagulation system.6,7 Although our study was not
powered to detect differences in thromboembolic com-
plications among the groups, the incidence of DVT seen
in this study was lower than that reported in other
patients with malignancy recovering from orthopedic
surgery while that of pulmonary embolism was greater
in our patients.17 Possible explanations for the differ-
ences in side effects between the two studies may be
that Lin et al.17 excluded patients undergoing extensive
spine surgery, had a larger sample size of patients and
did not use antifibrinolytic agents.
Our results are in contrast to a prior study showing a
benefit to using an identical dose regimen of aprotinin in
combination with moderate hypotensive anesthesia (sys-
tolic blood pressure between 80 to 90 mmHg) to reduce
blood loss and red blood cell transfusion in cancer pa-
tients undergoing major orthopedic surgery.8 In that
study of 23 patients, five of nine patients had malignancy
and received aprotinin and 16 patients had infected
hardware removed, of whom half were treated with
aprotinin. Although the authors reported a 58% reduc-
tion in the overall transfusion rate with aprotinin, it is
difficult to extrapolate their data to our population since
most of the patients had infection and few had cancer.8
Two other randomized, double-blind studies examined
the effects of aprotinin in noncancer patients undergo-
ing total hip replacement with general anesthesia.6,7
Both studies did not use controlled hypotension and
showed that aprotinin use was associated with similar
and modest reductions in blood loss. Only one of the
studies found that aprotinin reduced blood transfusion
requirements slightly and recommended its use,6 while
the other investigators questioned whether the slight
reduction in blood loss justified the routine use of an
expensive drug.7 More recent studies using aprotinin in
major orthopedic surgery showed that a “large” but not
“small” dose regimen of aprotinin as used in our study
was associated with a significant reduction of homolo-
gous PRBC use.9,10
We chose to include a group of patients treated with
EACA because it has been reported to have similar ben-
efits on blood loss and transfusion requirements as apro-
tinin in patients undergoing cardiovascular surgery, with
no reports of anaphylaxis and at a fraction of the cost.11
To the best of our knowledge, this is the first study to
compare EACA with placebo or aprotinin in a controlled
double-blind study of patients undergoing orthopedic
surgery. In contrast to aprotinin, which is a serine pro-
tease inhibitor that rapidly neutralizes plasmin, EACA
acts as a competitive inhibitor of plasmin by blocking
lysine sites on fibrinogen, fibrin and platelet receptors.
Tranexamic acid, an antifibrinolytic agent that works
similarly to EACA, has been used during orthopedic
surgery and shown to have little or no benefit in reduc-
ing blood loss or homologous blood transfusion
needs.18–20 Taken together, the above mentioned stud-
ies and our data suggest that the benefit of antifibrino-
lytic agents to reduce perioperative transfusion require-
ments in orthopedic surgery is not clear and perhaps
dose related.6–10,18–20
In conclusion, in this randomized, double-blind study
of patients with malignancy undergoing major orthope-
dic surgery we were unable to show that the use of
EACA or aprotinin is associated with a reduction of
341Antifibrinolytics And Orthopedic Surgery
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perioperative blood loss or transfusion requirements
when compared to placebo treated patients.
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